AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$SERA

Jackson Benjamin sold $4K of SERA

Jackson Benjamin (General Counsel) sold 2,190 shares of SERA PROGNOSTICS, INC. (SERA) at $2.00 on 2026-09-10.

Original reporting
SEC EDGAR · Jackson Benjamin
Published Sep 11, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The sale is modest and does not suggest a shift in company fundamentals.

02

Market read

Routine insider transaction with minimal trading relevance.

03

What to watch

Potential upcoming corporate events not disclosed that may have prompted the sale.

Relevance 3/10Novelty 3/10Timing: filing date 2026-09-11

Background

Form 4 filings disclose insider transactions; traders watch for material changes in insider holdings.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

General Counsel Jackson Benjamin sold 2,190 shares for $4,380, reducing his stake to 159,566 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size is small relative to market cap and typical insider activity.

Market effects

Sector

None; the sale does not affect the broader health‑tech sector.

Regional

None; SERA trades primarily on US exchanges.

Global

Low; limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Even small insider sells can signal concerns; monitor for further disposals.

Key entities

  • person
    Jackson Benjamin

    General Counsel of Sera Prognostics, Inc.

  • company
    Sera Prognostics, Inc.

    Medical diagnostics company listed on Nasdaq under ticker SERA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

AUG 19
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com2 min
AUG 12
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com6 min
AUG 12
$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K4 min